Biosimilars targeting Humira launched in the U.S. in early 2023 ... intends to shift to a hybrid in-person and virtual sales model by June 30, lowering its customer-facing staff.

AbbVie's flagship product, Humira, has been a key revenue driver ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ABBV is one of these AI-selected gems?

Novartis is looking to take full advantage of its branded and generics/biosimilar business model, with Cosentyx and a Humira biosimilar will help it provide a broader offering. "When patients are ...

BSC’s new pricing model which circumvents PBMs certainly lowers the price of Humira-referenced biosimilars substantially. This initiative could catch on and become a policy implemented by other ...

UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...

By partnering directly with manufacturers, the insurer aims to dramatically reduce the price of AbbVie's Humira, the ... introduces a new model called Pharmacy Care Reimagined.